Theraclion’s First Varicose Veins Treatment in Hong-Kong Opens Perspectives in Asia
November 22 2021 - 1:30PM
Business Wire
Regulatory News:
THERACLION (Paris:ALTHE) (ISIN: FR0010120402; Mnemo:
ALTHE), an innovative company developing a scalable robotic
platform for noninvasive echotherapy providing consistent, data
driven and evidence-based patient care, announces today the
completion of the first varicose veins echotherapy treatment in
China. The first milestone of our study, which will open the way to
Asian markets.
Kwong Wah Hospital is a major public hospital in Hong Kong, and
its vascular surgical team introduced endothermal ablation to Hong
Kong public hospitals. The study aims to demonstrate the efficacy
of SONOVEIN® as an innovative treatment method of varicose veins.
Dr. Maket Wong, Consultant Surgeon, and his two co-investigators,
Dr. SH Wong & Dr. A Fung, believe that the non-invasive
treatment, without scars nor incisions will be particularly coveted
by Asian patients. “The hospitals in Asia are often crowded. A
varicose vein treatment that avoids the use of an operating theatre
and provides an improved patient experience will be a game changer”
says Dr. Maket Wong.
Established experience on the Asian continent, through thyroid
tumor treatments in institutions such as the University of Hong
Kong Queen Mary Hospital, brings confidence to the management
team’s strategy. “We know that Hong Kong will be the gateway to the
Chinese market and a hub for the rest of Asia” explains David
Caumartin, CEO of Theraclion. “This territory is therefore uniquely
positioned to ensure a sound economic establishment for Asian
development.”
About Kwong Wah Hospital
Kwong Wah Hospital is a 1,141-bed public district general
hospital on the Kowloon peninsula, Hong Kong. The hospital was
founded by the Tung Wah Group in 1911, and managed by the Hospital
Authority since 1991. It provides a full range of medical services
to the population of West Kowloon and Wong Tai Sin.
About Theraclion
At Theraclion we believe that surgery, as we know it, is
outdated. It converts optimistic patients into anxious individuals,
brilliant doctors into exhausted system executors and stretches
healthcare systems to the limit. We have disrupted this convention
by creating extracorporeal treatment platforms. We replace surgery
with a robotic treatment from outside the body using High Intensity
Focussed Ultrasound (HIFU). Our leading edge echotherapy platforms
are currently CE marked in non-invasive treatment of varicose veins
with SONOVEIN® and of breast fibroadenomas and thyroid nodules with
Echopulse®.
Located in Malakoff, near Paris, our employees live and breath
innovation by extensive clinical research and harness artificial
intelligence. The market of varicose veins treatment alone requires
around 5 million procedures annually. It is a dynamic market in
which we change paradigms by making non-invasive echotherapy the
new standard.
For more information, please visit www.theraclion.com and our
patient website https://echotherapie.com/echotherapy/
Theraclion is listed on Euronext Growth Paris Mnemonic: ALTHE -
ISIN code: FR0010120402 LEI: 9695007X7HA7A1GCYD29
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211122006535/en/
Contacts Theraclion David Auregan Chief Operating Officer
david.auregan@theraclion.com Anja Kleber VP Marketing, Market
Access & Sales Francophonia anja.kleber@theraclion.com
Theraclion (EU:ALTHE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Theraclion (EU:ALTHE)
Historical Stock Chart
From Apr 2023 to Apr 2024